|
|
||||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
CLINICAL STUDIES |
From the Department of Pulmonary and Critical Care Medicine, University Otto-von-Guericke, Magdeburg, Germany, and the Department of Pulmonary Medicine, Medical School Hannover, Germany (Dr Burkhardt, Dr Welte); the Department of Clinical Pharmacology, University Rostock, Germany (Dr Majcher-Peszynska, Dr Mundkowski, Dr Drewelow); the Department of Clinical Chemistry and Pathobiochemistry, Free University Berlin, Germany (Dr Borner); and the College of Pharmacy, Department of Pharmaceutics, University of Florida, Gainesville (Dr Burkhardt, Dr Derendorf).
Ertapenem is approved for the treatment of community-acquired pneumonia (CAP), but its in vivo penetration into lung tissue (LT), epithelial lining fluid (ELF), and alveolar cells (AC) is unknown. Fifteen patients undergoing thoracotomy were treated with 1 g intravenously for perioperative prophylaxis. Bronchoalveolar lavage was performed 1, 3, and 5 hours after ertapenem infusion. Normal LT was sampled at the time of lung extraction. Blood was collected before and at different time points up to 24 hours after infusion. Mean concentrations of ertapenem in plasma, ELF, and AC were at 1.0 hour, 63.1, 4.06, 0.004 mg/L; at 3.0 hours, 39.7, 2.59, 0.003 mg/L; and at 5.0 hours, 27.2, 2.83, 0.007 mg/L. Mean (range) concentration in LT was 7.60 (2.5-19.4) mg/kg tissue 1.5 to 4.5 hours after infusion. In plasma, ertapenem exhibited a Cmax of 94.7 ± 23.3 mg/L and an AUC0-last of 501.1 ± 266.3 mgh/L. These results, combined with the reported (MIC)90 of most CAP bacteria, support the previously observed clinical efficacy of ertapenem in the treatment of CAP.
Key Words: Ertapenem pharmacokinetics plasma lung tissue ELF alveolar cells CAP
Address for reprints: Olaf Burkhardt, MD, College of Pharmacy, Department of Pharmaceutics, University of Florida, PO Box 100494, Gainesville, FL 32610.
![]()
CiteULike
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
O. Burkhardt, V. Kumar, D. Katterwe, J. Majcher-Peszynska, B. Drewelow, H. Derendorf, and T. Welte Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration J. Antimicrob. Chemother., February 1, 2007; 59(2): 277 - 284. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Burkhardt, M. Brunner, S. Schmidt, M. Grant, Y. Tang, and H. Derendorf Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis J. Antimicrob. Chemother., September 1, 2006; 58(3): 632 - 636. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Wittau, E. Wagner, V. Kaever, T. Koal, D. Henne-Bruns, and R. Isenmann Intraabdominal tissue concentration of ertapenem J. Antimicrob. Chemother., February 1, 2006; 57(2): 312 - 316. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |